It is well documented that there is a high prevalence of atherosclerotic disorders1,2) and their associated morbidity and mortality in cardiovascular disease3'4) in diabetes mellitus. Abnormal lipid and lipoprotein metabolism is also associated with this disease, presumably partly due to a defect in the removal of triglyceride-rich lipoproteins from plasma5.6). Lipoprotein lipase (LPL) partic ipates in the regulation of the plasma levels of both triglyceride-rich lipoporoteins and HDL7), and subspecies of apolipoprotein C (apo C) contribute to this mechanism, apo CII as an activator and, apo CIII as an inhibitor of this enzyme. where HbA1 was above 8% (Table 4) . Plasma triglyceride was highest in the good control group according to our data (Table 4) . Apo CIII0 in VLDL was highest in the poor control group and apo CII in VLDL was highest in the good control group (Table 5) . CIII2/CIII0 tended to be low depending on the level of HbA1. (Table 5 ). In the correlation of apo C subspecies to other parameters in this study on diabetes (Table 6 ), CIII0/CII showed a positive correlation to plasma triglyceride and cholesterol. In the group receiving oral medication (N = 20), CIII0/CII vs HDL-cholesterol showed a positive correlation, whereas CIII2/ CII vs plasma triglyceride showed an inverse correlation. In the insulin group (N=25), the percentage composition of CIII0 in VLDL apo C subspecies was inversely correlated to plasma cholesterol. In 38 diabetics whose HbA1 levels were also examined, CIII0/CII increased according to the elevation of HbA1. The percentage composition of CIII, in VLDL apo C subspecies was positively correlated to HbA1 level in the diet group but inversely correlated in the insulin group.
DISCUSSION
The present study demonstrates that serum lipids and lipids in various lipoprotein fractions differ according to treatment (diet, oral hypoglycemic drug or insulin). Severe metabolic derangement was seen in diabetics treated with the oral drug, as previously reported12). Similar differences according to treatment were also detected in the composition of apo C subspecies. As apo CII is an activator of lipoprotein lipase and apo CIII is an inhibitor of this enzyme, the compositional change of the apo C subspecies also accounts for the disturbance of Holdsworth et al.13) reported that VLDL rich in CIIIo was more susceptible to lipoprotein lipase than VLDL rich in CIII2. This suggests that the high content of CIII0 in VLDL in the oral drug group and in the poor control group of diabetes may be due to impaired lipoprotein lipase activity. In all diabetics, apo CIII0 in VLDL showed a positive correlation to plasma triglyceride (Table 6 ) and this correlation was also seen in the non-diabetic subjects (data not shown). However, this data showed some discrepancies in the relationship between apo CIII0 in VLDL and plasma triglyceride level, i.e., plasma triglyceride was highest in subjects whose HbA1 was under 8% (Table 4) , whereas apo CIII0 in VLDL was highest in subjects whose HbA1 was above 10% (Table 5) . Similar discrepancies between apo CHI, in VLDL and plasma triglyceride were also found in each therapy group (Table 7) .
These results suggest low sialylation of apo CIII in poorly controlled diabe tics exists independenty from plasma triglyceride levels. Low sialic acids content in cell membranes was also reported14,15) in diabetes mellitus. The sialylation of CIII0 ; apolipoprtein CIII0 % in VLDL ; TG, triglyeride (mg/100ml). In diabetics whose HbA1 was below 10%, CIII0 in VLDL and triglyceride were highest in the oral therapy group and CIII0 in VLDL seems to increase according to the elevation to plasma triglyceride levels. However, in each therapy group (oral drug and insulin), CIII0 in VLDL was higher in diabetics whose hemoglobin A, was above 10% than in those whose hemoglobin A, was below 10%, even though the former triglyceride level was lower than the latter.
apo CIII may be an important factor in the control of diabetes. Presumably, the oral drug itself may also play some part in decreasing the sialylation of apo CIII.
